(Q35082536)

6 August 2017

title

TET2 mutations in secondary acute myeloid leukemias: a French retrospective study (English)

1 reference

6 August 2017

Olivier Kosmider

1

1 reference

6 August 2017

Eric Delabesse

2

1 reference

6 August 2017

Véronique Mansat de Mas

3

1 reference

6 August 2017

Pascale Cornillet-Lefebvre

4

1 reference

6 August 2017

Odile Blanchet

5

1 reference

6 August 2017

Alain Delmer

6

1 reference

6 August 2017

Christian Recher

7

1 reference

6 August 2017

Sophie Raynaud

8

1 reference

6 August 2017

Didier Bouscary

9

1 reference

6 August 2017

Franck Viguié

10

1 reference

6 August 2017

Catherine Lacombe

11

1 reference

6 August 2017

Olivier A Bernard

12

1 reference

6 August 2017

Norbert Ifrah

13

1 reference

6 August 2017

François Dreyfus

14

1 reference

6 August 2017

Michaëla Fontenay

15

1 reference

6 August 2017

GOELAMS Investigators

16

1 reference

6 August 2017

publication date

20 April 2011

1 reference

6 August 2017

1 reference

6 August 2017

volume

96

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

1059-1063

1 reference

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

6 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Acquired mutations in TET2 are common in myelodysplastic syndromes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Mutation in TET2 in myeloid cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3128227

Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor progno

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21508122

12 December 2020

inferred from PubMed ID database lookup

Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21508122

12 December 2020

inferred from PubMed ID database lookup

Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21508122

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.3324/HAEMATOL.2011.040840

1 reference

release_wfaktr7h7bcolittkzlvl2mvgm

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wfaktr7h7bcolittkzlvl2mvgm

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3128227

1 reference

6 August 2017

1 reference